Compliance

Written Procedures

THIS PAGE IS UNDER DEVELOPMENT AS OF NOVEMBER 2018. CHECK BACK AFTER JANUARY 2019 FOR UPDATES.

IRBs must comply with HHS and FDA regulations in 45 CFR part 46 and 21 CFR parts 50 and 56, respectively, when reviewing research subject to those regulations. Both the HHS regulations at 45 CFR 46.103(b)(4) and (5) and the FDA regulations at 21 CFR 56.108(a) and (b) state that IRBs must follow written procedures for the following functions and operations:

  1. Conducting initial and continuing review of research and reporting findings and actions to the investigator and the institution;
  2. Determining which projects require review more often than annually and determining which projects need verification from sources other than the investigator that no material changes have occurred since previous IRB review;
  3. Ensuring prompt reporting to the IRB of proposed changes in a research activity and ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval except where necessary to eliminate apparent immediate hazards to the human subjects;
  4. Ensuring prompt reporting to the IRB, appropriate institutional officials, and the department or agency head (i.e., OHRP) for research conducted or supported by HHS, and FDA for FDA-regulated research of any:
  • Unanticipated problems involving risks to human subjects or others;
  • Instance of serious or continuing noncompliance with the applicable HHS and FDA regulations or the requirements or determinations of the IRB;
  • Suspension or termination of IRB approval.

Initial Review

Status Reporting (formerly known as: Continuing Review)

Amendments (also known as: Modifications)

Unanticipated Problems

Serious or Continuing Noncompliance

Suspension or Termination